CN110904087B - L-阿拉伯糖差向异构酶突变体及其应用 - Google Patents

L-阿拉伯糖差向异构酶突变体及其应用 Download PDF

Info

Publication number
CN110904087B
CN110904087B CN201911383972.2A CN201911383972A CN110904087B CN 110904087 B CN110904087 B CN 110904087B CN 201911383972 A CN201911383972 A CN 201911383972A CN 110904087 B CN110904087 B CN 110904087B
Authority
CN
China
Prior art keywords
ala
leu
gly
val
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911383972.2A
Other languages
English (en)
Other versions
CN110904087A (zh
Inventor
柳志强
孙晨奕
贾东旭
郑裕国
金利群
彭晨
陈德水
廖承军
程新平
李勉
毛宝兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University of Technology ZJUT
Original Assignee
Zhejiang University of Technology ZJUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University of Technology ZJUT filed Critical Zhejiang University of Technology ZJUT
Priority to CN201911383972.2A priority Critical patent/CN110904087B/zh
Publication of CN110904087A publication Critical patent/CN110904087A/zh
Application granted granted Critical
Publication of CN110904087B publication Critical patent/CN110904087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/02Monosaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/24Preparation of compounds containing saccharide radicals produced by the action of an isomerase, e.g. fructose
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y503/00Intramolecular oxidoreductases (5.3)
    • C12Y503/01Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01004L-Arabinose isomerase (5.3.1.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明涉及一种L‑阿拉伯糖差向异构酶突变体,及其在微生物催化D‑半乳糖异构化制备D‑塔格糖中的应用。所述L‑阿拉伯糖差向异构酶突变体,由所示氨基酸经定点突变而得,所述点突变位点为下列中的一个或多个:(1)第97位、(2)第189位、(3)第301位、(4)第409位和(5)第462位。本发明有益效果主要体现在:本发明提供了一种全新的差向异构酶及其突变体,以及其在制备塔格糖(D‑tagatose)中的应用。该突变体具有高最适反应温度80℃,解决了现有酶无法在高温生产D‑tagatose的技术难题。使用本突变体生产D‑tagatose,底物浓度为600g/L时,产物得率最高可达79.7%,优于原始酶和其他突变酶的转化效果,具有较好工业应用前景。

Description

L-阿拉伯糖差向异构酶突变体及其应用
(一)技术领域
本发明涉及一种L-阿拉伯糖差向异构酶突变体,及其在微生物催化D-半乳糖异构化制备D-塔格糖中的应用。
(二)背景技术
D-塔格糖(D-tagatose)是自然界中发现的稀有己酮糖,是D-半乳糖的异构体。它最早被发现存在于一种热带长青植物的树胶中,后来在酸奶、奶酪中也有发现。D-tagatose具有甜度高、热量低、吸收率低、有效降低血糖及抗龋齿、改善肠道菌群等性质与功效。美国食品及药物管理局已通过对D-tagatose的安全认证,准许其用于食品中。D-tagatose的生产方法主要有化学法和生物法。化学法存在成本高、酸碱用量高、污染严重、产物成分复杂、分离纯化难等问题。相比之下,生物法制备D-tagatose更具有优势,近年来逐渐成为研究热点。
生物法制备D-tagatose的工艺是以D-半乳糖为原料,利用L-阿拉伯糖异构酶(L-arabinose isomerase,简称LAI)进行催化反应,一步法生成D-tagatose。其中,原料D-半乳糖廉价易得、整体反应过程温和易控、反应过程符合环保要求,是一种替代化学法的最优制糖方法。研究报道指出,高温和弱酸性的反应条件更有利于D-tagatose的生物转化。当前,生物法催化D-半乳糖制备D-tagatose时底物浓度偏低,均处于100g/L以下,不利于应用到工业化生产中。当前,LAI制备D-tagatose存在的问题是酶源少,催化效率有待提高。
由于异构酶本身作用环境和对象的多样化,通常具备底物谱广泛的优势,可以由一种异构酶催化制备多种糖产品,这为研制针对特定糖的异构酶催化剂提供了新的途径。以核酸、蛋白质等生物大分子数据库为主要对象,辅助计算机对生物信息进行比较分析,获取基因编码、蛋白质结构功能及其相互关系等理性信息,筛选新型异构酶制剂,探索异构酶的底物谱,开发异构酶的新功能,将分子改造获得的高效生物催化剂用于制备高浓度D-psicose,对于满足人民群众日益增长的摄糖需求具有重要意义。
(三)发明内容
本发明目的是提供一种最适反应温度高且收率高的L-阿拉伯糖异构酶异构体突变体,及其在微生物催化D-半乳糖异构化制备D-塔格糖中的应用。
本发明采用的技术方案是:
一种L-阿拉伯糖差向异构酶突变体,由序列如SEQ ID NO.5所示氨基经定点突变而来,所述突变的位点为下列中的一个或多个:(1)第97位、(2)第189位、(3)第301位、(4)第409位、(5)第462位。
优选的,所述突变体由序列如SEQ ID NO.5所示氨基酸经下列之一或多个位点突变而得:(1)第97位甘氨酸G突变为天冬酰胺N、精氨酸R、赖氨酸K、天冬氨酸D或半胱氨酸C,(2)第189位天冬氨酸N突变为丝氨酸S、谷氨酰胺Q、甘氨酸G或组氨酸H,(3)第301位亮氨酸L突变为异亮氨酸I、蛋氨酸M或谷氨酸E,(4)第409位亮氨酸L突变为苯丙氨酸F、脯氨酸P或丝氨酸S,(5)第462位苏氨酸T突变为丙氨酸A、色氨酸W或酪氨酸Y。
进一步,所述L-阿拉伯糖差向异构酶突变体由序列如SEQ ID NO.5所示氨基酸经下列之一或多个位点突变而得:(1)第97位甘氨酸G突变为赖氨酸K,(2)第189位天冬氨酸N突变为丝氨酸S,(3)第301位亮氨酸L突变为谷氨酸E,(4)第409位亮氨酸L突变为脯氨酸P,(5)第462位苏氨酸T突变为丙氨酸A。
更为优选的,所述L-阿拉伯糖差向异构酶突变体序列如SEQ ID NO.7所示(编码基因如SEQ ID NO.8所示)。
本发明还涉及所述L-阿拉伯糖差向异构酶突变体在催化D-半乳糖异构化制备D-塔格糖中的应用。
具体的,所述应用为:以含L-阿拉伯糖差向异构酶编码基因的重组基因工程菌经发酵培养获得的湿菌体或湿菌体经超声破碎后获得的上清液为催化剂,以D-半乳糖为底物,在Mn2+存在下,在6.0~7.0的50mMNa2HPO4-NaH2PO4缓冲液中,70~85℃温度下反应,反应结束后,反应液分离纯化,获得D-塔格糖。
所述L-阿拉伯糖差向异构酶突变体编码基因序列优选如SEQ ID NO.8所示。
本发明有益效果主要体现在:本发明提供了一种全新的差向异构酶及其突变体,以及其在催化D-半乳糖异构化制备D-塔格糖(D-tagatose)中的应用。该突变体具有高最适反应温度80℃,解决了现有酶无法在高温生产D-tagatose的技术难题。使用本突变体生产D-tagatose,产物得率最高可达79.7%,优于原始酶和其他突变酶的转化效果,具有较好工业应用前景。
(四)附图说明
图1为重组酶的最适温度示意图;
图2为金属离子对重组酶活力的影响示意图;
(五)具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此:
实施例1:新型酶的筛选
1、酶的来源与重组菌的构建
从NCBI数据库中获得糖异构酶,分别来源于分别来源于Salegentibacteragarivorans(GenBank编号WP_093303409.1)、Massilia glaciei(GenBank编号WP_106758181.1)、Chitinophagaceae bacterium(GenBank编号WP_153799928.1),并命名为SaLAI、MgLAI和CbLAI。根据氨基酸序列,依据大肠杆菌密码子偏好性进行密码子优化,通过基因工程的常规操作以全合成的方法合成了三条选择的核苷酸序列,分别如SEQ ID NO.2、SEQ ID NO.4和SEQ ID NO.6所示;编码酶的氨基酸序列分别如SEQ ID NO.1、SEQ ID NO.3和SEQ ID NO.5所示。在核酸序列末端加入6×His-tag标签,两端加入酶切位点XbaI和XhoI,将该基因克隆至pET28b(+)对应的XbaI和Xho I位点,获得重组表达质粒pET28b/SaLAI、pET28b/MgLAI和pET28b/CbLAI。
2、重组菌的筛选与诱导
将获得的重组表达质粒pET28b/SaLAI、pET28b/MgLAI和pET28b/CbLAI转化至Escherichia coli BL21(DE3)受体菌中,涂布于含终浓度为100μg/mL卡那霉素的琼脂平板上,37℃下培养过夜,第2天于平板上长出的菌落中随机挑取克隆并抽提质粒进行琼脂糖凝胶电泳鉴定,获得含LAI基因的基因工程菌。
LB液体培养基组成:胰蛋白胨10g/L,酵母粉5g/L,NaCl 10g/L,溶剂为水,pH值自然;LB固体培养基在LB液体培养基中添加15g/L琼脂;121℃高压灭菌20min;使用前添加终浓度100μg/mL卡那霉素。
将基因工程菌接种至含终浓度100μg/mL卡那霉素的LB液体培养基,在37℃、150r/min培养至OD600约0.6~0.8,获得种子液;将种子液以体积浓度2%(v/v)接种量接种至新鲜的含有终浓度100μg/mL卡那霉素的LB培养基中,于37℃、150r/min培养OD600至0.4~-0.6,再向培养液中加入终浓度为1.2mM的IPTG,于28℃下诱导表达12h后,4℃、6000r/min离心10min,弃去上清液,用0.85%的生理盐水清洗两遍湿菌体,并收集湿菌体,备用。
3、底物特异性地研究
各取1g上述重组菌湿菌体,用50mL 50mM Na2HPO4-NaH2PO4(pH 6.5)缓冲液悬浮,在39W条件下超声破碎,有效时间15min,制备获得超声破碎后的混悬液,离心,收集上清液,取1mL上清液用于反应。反应体系:50mM Na2HPO4-NaH2PO4缓冲液(pH 6.5)、0.5mMCoCl2.6H2O、0.5mM MnCl2、0.5mM FeCl2、0.5mM MgCl2和50g/L的各种底物(见表1)、50μL上述上清液,共1mL体系。反应条件:于40℃条件下反应10min,沸水煮沸10min终止反应。12000r/min离心10min,取上清液。
对于各个底物的活力测定采用半胱氨酸-咔唑法。取一定浓度的糖溶液,依次加入0.1mL的1.5%(w/v)半胱氨酸盐酸盐溶液、3mL 75%(w/w)浓硫酸溶液、0.1mL的0.12%(w/v)咔唑乙醇溶液,60℃下保温10min,于波长560nm下测定吸光度值,并作空白对照。每min内糖底物异构化生成1μmol糖产物所需酶量定义为一个酶活单位(U)。将SaLAI对L-阿拉伯糖测定的酶活设定为100%。由表1结果可知,CbLAI对D-半乳糖具有较高酶活,说明该酶更具备催化D-半乳糖至D-tagatose的异构化反应能力。
表1:各酶的底物特异性研究
Figure BDA0002343025340000051
4、重组菌酶活的精准测定
采用超声破碎方法对湿菌体进行超声破碎,取1g制备的湿菌体,用50mL50mMNa2HPO4-NaH2PO4缓冲液(pH 6.5)悬浮,在39W条件下超声破碎15min,制备获得超声破碎后的混悬液,离心,收集上清液,取1mL上清液用于反应。反应体系:50mM Na2HPO4-NaH2PO4缓冲液(pH 6.5)、1mM MnCl2和50g/L的D-半乳糖及50μL上述上清液,共1mL体系。反应条件:于40℃条件下反应10min,沸水煮沸10min终止反应,稀释10倍后,使用0.22μm滤膜过膜;采用HPLC检测D-tagatose浓度。分析柱为AminexHPX-87H柱(300×7.8mm,9μm,伯乐生命医学产品有限公司)。Waters 2414示差折光检测器,Waters 1525泵,Waters 717进样器。酶活定义:40℃和pH 6.5下,每分钟将D-半乳糖异构化生成1μmol D-塔格糖所需酶量定义为一个酶活单位(U)。
表2:重组酶的酶活测定
Figure BDA0002343025340000052
实施例2:CbLAI单位点突变体的构建与筛选
1、突变体构建
根据CbLAI亲本序列(氨基酸序列为SEQ ID NO.5所示,核苷酸序列为SEQ ID NO.6所示)设计定点突变的突变引物,利用快速PCR技术,以重组载体pET28b/CbLAI为模板,对第97位引入单突变,引物为:
正向引物97G:CCGGCAAAGATGTGGATCGGTNNNCTAAAAGTAC(下划线为突变碱基)
反向引物97G:GTACTTTTAGNNNACCGATCCACATCTTTGCCGG(下划线为突变碱基)
PCR反应体系:2×Phanta Max Buffer(含Mg2+)25μL,dNTPs 10mM,正向引物97G 2μL(5pmol/μL,下同),反向引物97G 2μL(5pmol/μL,下同),模板DNA 1μL(20ng/μL,下同),Phanta Max Super-Fidelity DNA Polymerase 50U,加入ddH2O至50μL。
PCR扩增条件为95℃3min;(95℃15s,65℃15s,72℃6.5min)30循环;72℃5min。
2、突变体转化表达
取5μL的PCR产物,加入100μL冰浴的E.coli BL21(DE3)感受态细胞悬液中,冰上静置30min,将转化产物于42℃热击90s,迅速置于冰上冷却5min,向管中加入600μL的LB液体培养基,37℃、150r/min培养60min,取100μL上述菌液涂板,待菌液完全被培养基吸收后,37℃倒置培养12h。
3、高通量筛选阳性转化子
反应混合液组成:50mM Na2HPO4-NaH2PO4缓冲液(pH 6.5)、1mM MnCl2和5g/L的D-半乳糖。在96孔聚苯乙烯微孔培养板中每孔加入100μL含有终浓度100μg/mL卡那霉素的LB培养液,接种不同的转化菌落,于37℃、150r/min培养OD600至0.4~0.6,再向培养液中加入终浓度为1.2mM的IPTG,于28℃下诱导表达10h后,4℃、6000r/min离心10min,弃去上清液。取50μL上述反应混合液加入含有菌体的的96孔板中,振荡器振荡混匀后在40℃、600r/min反应10min,冰浴10min停止反应。取2.5μL反应液以半胱氨酸-咔唑显色法筛选突变体,反应体包括反应液5μL的1.5%(w/v)半胱氨酸盐酸盐,150μL的70%(w/w)浓硫酸、5μL的0.12%(w/v)咔唑乙醇,60℃下保温10min后观察颜色变化。以重组菌E.coli BL21(DE3)/pET28b/CbLAI的反应为对照,取颜色比E.coli BL21(DE3)/pET28b/CbLAI的反应深的突变株进行酶活精准测定。
4、阳性转化子酶活的精准测定
操作同实施例1的“重组菌酶活的精准测定”。
该实施例的结果为:对513株重组转化菌初筛,筛选出5株酶活提高的突变株,再对其进行酶活精准测定,具体结果见表3。经分析确定,其余508株重组菌酶活保持不变或下降的原因是第97位甘氨酸(G)突变为N、R、K、D和C的其他氨基酸。
表3:单点突变重组菌的酶活测定
Figure BDA0002343025340000071
将酶活提高最多的CbLAI突变体-G97K记为CbLAI-1,获得重组菌E.coli BL21(DE3)/pET28b/CbLAI-1。
实施例3:CbLAI双位点突变体的构建与筛选
根据实施例2构建的单突变体CbLAI-1序列设计定点突变的突变引物,利用快速PCR技术,以重组载体pET28b/CbLAI-1为模板,对第189位引入单突变,引物为:
正向引物189N:TTCGGCGACNNNATGAGACAAGTAGCAGTGACAG(下划线为突变碱基)
反向引物189N:CTGTCACTGCTACTTGTCTCATNNNGTCGCCGAA(下划线为突变碱基)
PCR反应体系:2×Phanta Max Buffer(含Mg2+)25μL,dNTPs 10mM,正向引物189N 2μL,反向引物189N 2μL,模板DNA 1μL,Phanta Max Super-Fidelity DNA Polymerase 50U,加入ddH2O至50μL。
PCR扩增条件为95℃3min;(95℃15s,62.5℃15s,72℃6.5min)30循环;72℃5min。
PCR产物转化E.coli BL21(DE3)感受态细胞,挑单克隆于含100μg/mL卡那霉素的LB液体培养基中,37℃培养过夜。利用半胱氨酸咔唑法显色法对突变体进行初筛(操作同实施例2的“高通量筛选阳性转化子”)。
采用超声破碎方法对湿菌体进行超声破碎,并进行酶活精准测定(操作同实施例2的“阳性转化子酶活测定”)。
该实施例的结果为:对490株重组转化菌初筛,筛选出4株酶活提高的突变株,再对其进行酶活精准测定,具体结果见表4。经分析确定,其余486株重组菌酶活保持不变或下降的原因是第189位天冬氨酸(N)突变为S、Q、G和H外的其他氨基酸。
表4:双点突变重组菌的酶活测定
Figure BDA0002343025340000081
将酶活提高最多的CbLAI突变体-G97K-N189S记为CbLAI-2,获得重组菌E.coliBL21(DE3)/pET28b/CbLAI-2。
实施例4:CbLAI三位点突变体的构建与筛选
根据实施例3构建的突变体CbLAI-2序列设计定点突变的突变引物,利用快速PCR技术,以重组载体pET28b/CbLAI-2为模板,对第301位引入单突变,引物为:
正向引物301L:TATTGCCACGCAACGCNNNATGGCAGATGGCTA(下划线为突变碱基)
反向引物301L:TAGCCATCTGCCATNNNGCGTTGCGTGGCAATA(下划线为突变碱基)
PCR反应体系:2×Phanta Max Buffer(含Mg2+)25μL,dNTPs 10mM,正向引物301L 2μL,反向引物301L 2μL,模板DNA 1μL,Phanta Max Super-Fidelity DNA Polymerase 50U,加入ddH2O至50μL。
PCR扩增条件为95℃3min;(95℃15s,64℃15s,72℃6.5min)30循环;72℃5min。
PCR产物转化E.coli BL21(DE3)感受态细胞,挑单克隆于含100μg/mL卡那霉素的LB液体培养基中,37℃培养过夜。利用半胱氨酸咔唑法显色法对突变体进行初筛(操作同实施例2的“高通量筛选阳性转化子”)。
采用超声破碎方法对湿菌体进行超声破碎,并进行酶活精准测定(操作同实施例2的“阳性转化子酶活测定”)。
该实施例的结果为:对356株重组转化菌初筛,筛选出3株酶活提高的突变株,再对其进行酶活测定,具体结果见表5。经分析确定,其余353株重组菌酶活保持不变或下降的原因是第301位亮氨酸(L)突变为I、M和E外的其他氨基酸。
表5:三点突变重组菌的酶活测定
Figure BDA0002343025340000091
Figure BDA0002343025340000101
将酶活提高最多的CbLAI突变体-G97K-N189S-L301E记为CbLAI-3,获得重组菌E.coli BL21(DE3)/pET28b/CbLAI-3。
实施例5:CbLAI四位点突变体的构建与筛选
根据实施例4构建的突变体CbLAI-3序列设计定点突变的突变引物,利用快速PCR技术,以重组载体pET28b/CbLAI-3为模板,对第409位引入单突变,引物为:
正向引物409L:CAGATTCAGGNNNTTAGTAAATGAAGTGGAGGCG(下划线为突变碱基)
反向引物409L:CGCCTCCACTTCATTTACTAANNNCCTGAATCTG(下划线为突变碱基)
PCR反应体系:2×Phanta Max Buffer(含Mg2+)25μL,dNTPs 10mM,正向引物409L 2μL,反向引物409L 2μL,模板DNA 1μL,Phanta Max Super-Fidelity DNA Polymerase 50U,加入ddH2O至50μL。
PCR扩增条件为95℃3min;(95℃15s,61℃15s,72℃6.5min)30循环;72℃5min。
PCR产物转化E.coli BL21(DE3)感受态细胞,挑单克隆于含100μg/mL卡那霉素的LB液体培养基中,37℃培养过夜。利用半胱氨酸咔唑法显色法对突变体进行初筛(操作同实施例2的“高通量筛选阳性转化子”)。
采用超声破碎方法对湿菌体进行超声破碎,并进行酶活精准测定(操作同实施例2的“阳性转化子酶活测定”)。
该实施例的结果为:对586株重组转化菌初筛,筛选出3株酶活提高的突变株,再对其进行酶活测定,具体结果见表6。经分析确定,其余585株重组菌酶活保持不变或下降的原因是第409位亮氨酸(L)突变为F、P和S外的其他氨基酸。
表6:四位点突变重组菌的酶活测定
Figure BDA0002343025340000111
将酶活提高最多的CbLAI突变体-G97K-N189S-L301E-L409P记为CbLAI-4,获得重组菌E.coli BL21(DE3)/pET28b/CbLAI-4。
实施例6:CbLAI五位点突变体的构建与筛选
根据实施例5构建的突变体CbLAI-4序列设计定点突变的突变引物,利用快速PCR技术,以重组载体pET28b/CbLAI-4为模板,对第462位引入单突变,引物为:
正向引物462T:TTCTCAGAACCTTNNNGCGGAACATCTCGAGG(下划线为突变碱基)
反向引物462T:CCTCGAGATGTTCCGCNNNAAGGTTCTGAGAA(下划线为突变碱基)
PCR反应体系:2×Phanta Max Buffer(含Mg2+)25μL,dNTPs 10mM,正向引物462T 2μL,反向引物462T 2μL,模板DNA 1μL,Phanta Max Super-Fidelity DNA Polymerase 50U,加入ddH2O至50μL。
PCR扩增条件为95℃3min;(95℃15s,59.5℃15s,72℃6.5min)30循环;72℃5min。
PCR产物转化E.coli BL21(DE3)感受态细胞,挑单克隆于含100μg/mL卡那霉素的LB液体培养基中,37℃培养过夜。利用半胱氨酸咔唑法显色法对突变体进行初筛(操作同实施例2的“高通量筛选阳性转化子”)。
采用超声破碎方法对湿菌体进行超声破碎,并进行酶活精准测定(操作同实施例2的“阳性转化子酶活测定”)。
该实施例的结果为:对438株重组转化菌初筛,筛选出3株酶活提高的突变株,再对其进行酶活测定,具体结果见表7。经分析确定,其余435株重组菌酶活保持不变或下降的原因是第462位苏氨酸(T)突变为A、W和Y外的其他氨基酸。
表7:五点突变重组菌的酶活测定
Figure BDA0002343025340000121
将酶活提高最多的CbLAI突变体-G97K-N189S-L301E-L409P-T462A记为CbLAI-5,获得重组菌E.coli BL21(DE3)/pET28b/CbLAI-5。
实施例7:重组大肠杆菌发酵产酶与纯化
分别将重组菌E.coli BL21(DE3)/pET28b/CbLAI、E.coli BL21(DE3)/pET28b/CbLAI-1、E.coli BL21(DE3)/pET28b/CbLAI-2、E.coli BL21(DE3)/pET28b/CbLAI-3、E.coli BL21(DE3)/pET28b/CbLAI-4、E.coli BL21(DE3)/pET28b/CbLAI-5接种至含终浓度100μg/mL卡那霉素的LB液体培养基,在37℃、150r/min培养OD600约0.6~0.8,获得种子液;将种子液以2%(v/v)接种量接种至新鲜的含有终浓度100μg/mL卡那霉素的LB液体培养基中,于37℃、150r/min培养OD600至0.4~0.6,再向培养液中加入终浓度为1.2mM的IPTG,于28℃下诱导表达12h后,4℃、6000r/min离心10min,弃去上清液,用0.85%的生理盐水清洗两遍湿菌体,并收集湿菌体,备用。采用超声破碎方法对湿菌体进行超声破碎,收集上清液(操作同实施例1的“重组酶酶活的精准测定”)。
使用nickel-NTA琼脂糖凝胶柱进行纯化,用平衡缓冲液(20mM磷酸盐缓冲液,300mM NaCl,20mM咪唑,pH 8.0)平衡层析柱,再使用洗脱液(50mM磷酸盐缓冲液,300mMNaCl,500mM咪唑,pH 8.0)进行洗脱,根据紫外检测器的信号响应,收集相应的洗脱液,即为各自纯酶液。
实施例8:纯化CbLAI及其突变体的最适反应温度
将实施例7中的纯酶液作为转化用酶,测定酶的最适反应温度。具体操作如下:50mM Na2HPO4-NaH2PO4缓冲液(pH 6.5)中,加入50g/L D-半乳糖、1mM MnCl2和50μL纯酶液,体系共1mL。分别于不同转化温度:65、70、75、80、85、90、95℃测定重组LAI的活力(方法同实施例1的“重组菌的酶活精准测定”)。将各自(酶)的最高酶活设定为100%。由图2中可知,CbLAI-5在80℃具有最高酶活,比原始酶CbLAI在65℃提高了15℃。
实施例9:金属离子对最优突变体酶活的影响
将实施例7中的纯酶液作为转化用酶,测定金属离子对重组酶酶活的影响,所选单金属离子(阴离子为Cl-):Co2+、Mg2+、Mn2+、Cu2+、Zn2+、Ba2+、Fe2+、Ni2+、Pb2+和Ca2+。1mL反应体系包括:50mM Na2HPO4-NaH2PO4缓冲液(pH6.5)、50g/L D-半乳糖、50μL纯酶液和1mM不同金属离子。于40℃测定LAI的活力,以不加金属离子作为对照。由图2可知,Mn2+对LAI的酶活有极大的促进作用。
实施例10:原始酶与突变酶突变重组菌全细胞制备D-tagatose
按实施例4的方法,获得重组菌E.coli BL21(DE3)/pET28b/CbLAI、E.coli BL21(DE3)/pET28b/CbLAI-1、E.coli BL21(DE3)/pET28b/CbLAI-2、E.coli BL21(DE3)/pET28b/CbLAI-3、E.coli BL21(DE3)/pET28b/CbLAI-4、E.coli BL21(DE3)/pET28b/CbLAI-5湿菌体作为生物催化剂,以D-半乳糖为底物,生物转化制备D-tagatose。催化体系包括:不同浓度的D-半乳糖、1mM MnCl2、10g/L湿菌体,再加入适量50mM Na2HPO4-NaH2PO4(pH 6.5)缓冲液至总体系100mL。反应体系于65℃、150r/min条件下反应8h。每隔1h取样、离心,用0.22μm膜过滤后进行HPLC检测D-tagatose浓度。由表8可知,E.coli BL21(DE3)/pET28b/CbLAI-5的产物得率最终达到79.7%,高于原始酶E.coli BL21(DE3)/pET28b/CbLAI和其他突变酶的得率。
表8:各重组菌得率的比较
Figure BDA0002343025340000141
序列表
<110> 浙江工业大学
<120> L-阿拉伯糖差向异构酶突变体及其应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 508
<212> PRT
<213> Salegentibacter agarivorans
<400> 1
Met Ile Asn Ile Glu Ala Lys Glu Ile Trp Phe Val Thr Gly Ser Gln
1 5 10 15
His Leu Tyr Gly Asp Glu Thr Leu Asn Gln Val Ala Ala Asp Ser Lys
20 25 30
Ala Ile Val Asn Gly Leu Asn Glu Ser Lys His Leu Pro Leu Lys Ile
35 40 45
Val Trp Lys Asp Thr Val Lys Thr Ala Asp Glu Ile Thr Asp Ile Cys
50 55 60
Gln Asp Ala Asn Ala Asn Lys Asn Cys Ile Gly Ile Val Ala Trp Met
65 70 75 80
His Thr Phe Ser Pro Ala Lys Met Trp Ile Lys Gly Leu Ser Leu Leu
85 90 95
Lys Lys Pro Leu Cys His Leu His Thr Gln Phe Asn Ala Glu Ile Pro
100 105 110
Trp Gly Lys Ile Asp Met Asp Tyr Met Asn Leu His Gln Ser Ala His
115 120 125
Gly Asp Arg Glu Phe Gly Phe Met Met Ser Arg Met Arg Lys Lys Arg
130 135 140
Lys Val Ile Val Gly His Trp Lys Thr Asp Arg Val Gln Gln Lys Leu
145 150 155 160
Gly Ile Trp Ser Arg Val Val Leu Gly Trp Asp Glu Leu Gln His Leu
165 170 175
Lys Val Ala Arg Ile Gly Asp Asn Met Arg Asn Val Ala Val Thr Glu
180 185 190
Gly Asp Lys Val Ala Ala Glu Met Lys Phe Gly Met Ala Val Asn Gly
195 200 205
Tyr Asp Ser Ser Glu Val Val Ala His Ile Asp Lys Ile Ser Glu Glu
210 215 220
Lys Ile Asn Glu Leu Leu Lys Lys Tyr Glu Ala Asp Tyr Asn Leu Ser
225 230 235 240
Gln Asp Leu Lys Glu Gly Gly Ser Gln Arg Asp Ser Leu Val Asp Ala
245 250 255
Ala Lys Ile Glu Leu Gly Leu Arg Ser Phe Leu Asp Glu Gly Gly Phe
260 265 270
Lys Ala Phe Thr Asp Thr Phe Glu Asn Leu Gly Lys Leu Lys Gln Leu
275 280 285
Pro Gly Ile Ala Val Gln Arg Leu Met Ala Asp Gly Tyr Gly Phe Gly
290 295 300
Ala Glu Gly Asp Trp Lys Thr Ala Ala Leu Leu Arg Ala Met Lys Val
305 310 315 320
Met Ala Val Gly Leu Glu Glu Gly Thr Ser Phe Met Glu Asp Tyr Thr
325 330 335
Tyr His Phe Thr Pro Gln Lys Ser Tyr Val Leu Gly Ser His Met Leu
340 345 350
Glu Ile Cys Pro Ser Ile Ala Asp Ala Lys Pro Thr Cys Glu Val His
355 360 365
Pro Leu Gly Ile Gly Gly Lys Glu Asp Pro Val Arg Leu Val Phe Asn
370 375 380
Ala Pro Lys Gly Asp Ala Leu Asn Ala Ser Leu Ile Asp Met Gly Asn
385 390 395 400
Arg Phe Arg Leu Ile Val Asn Glu Val Glu Ala Val Ala Pro Glu Ala
405 410 415
Asp Leu Pro Asn Leu Pro Val Ala Arg Val Leu Trp Asp Ala Lys Pro
420 425 430
Asn Leu Glu Val Ala Ala Thr Ser Trp Ile Leu Ala Gly Gly Ala His
435 440 445
His Thr Val Tyr Thr Gln Ala Leu Thr Thr Glu Phe Leu Glu Asp Phe
450 455 460
Ala Asp Ile Ala Gly Ile Glu Leu Leu Val Ile Asp Asp Lys Thr Ser
465 470 475 480
Ile Arg Glu Phe Lys Asp Lys Ile Asn Ala Asn Glu Ala Tyr Tyr His
485 490 495
Met Phe Gln His Gly Met His His His His His His
500 505
<210> 2
<211> 1524
<212> DNA
<213> Salegentibacter agarivorans
<400> 2
atgattaata tcgaagctaa agagatatgg tttgttactg gttctcaaca tttatatggc 60
gatgaaacct tgaaccaggt cgccgcagac tccaaggcga ttgtaaatgg acttaacgag 120
tcaaaacacc tccctctaaa gatcgtgtgg aaagatacag ttaagacggc tgacgaaata 180
actgatattt gtcaagacgc caatgcaaac aaaaattgca tcgggatagt cgcgtggatg 240
cataccttct cgcccgctaa gatgtggatt aaaggtctga gtttattgaa gaaaccactt 300
tgtcacctcc atacacagtt taacgccgag atcccgtggg gcaagataga tatggactac 360
atgaatctac accaaagcgc acatggagat cgtgaattcg ggtttatgat gtctcgcatg 420
cgaaaaaagc ggaaagtaat tgtgggtcac tggaagacgg acagagttca gcaaaaactg 480
ggcatctggt ccagggtcgt attaggatgg gatgagttgc agcatcttaa ggtggcgcgt 540
ataggggaca acatgcgcaa tgttgctgtc actgaaggtg ataaagtagc cgcagagatg 600
aagttcggca tggcggtgaa cggatatgac tcatcggaag ttgtcgctca cattgataaa 660
atcagtgagg aaaagataaa tgagctccta aaaaagtacg aagccgacta taacctgagc 720
caagatttaa aagagggggg ttctcagcga gactccttgg tagatgcagc gaagattgaa 780
cttggcctcc ggtcatttct agacgaggga gggttcaaag cttttaccga tacattcgaa 840
aatctgggta agttaaaaca attgcctggc atcgccgtgc agagacttat ggcagacgga 900
tacgggtttg gtgcggaggg cgattggaag acggctgccc tcctaagggc aatgaaagtt 960
atggcggtcg gactggaaga ggggacttcg ttcatggaag actataccta ccattttaca 1020
ccccaaaaga gttatgtatt aggtagccac atgttggaga tatgcccatc tattgctgat 1080
gccaaaccga cgtgtgaagt gcatcctctt ggcatcggag ggaaggagga ccccgttcgt 1140
ctcgtcttca acgcaccaaa aggtgatgcg ctaaatgctt ccctgataga catgggcaac 1200
cgctttcgat taattgtaaa tgaagtggag gccgttgcac cggaagcgga tttgcctaac 1260
cttcccgtcg ctcgggtact ctgggacgcc aagccaaatc tagaggtggc agcgacttca 1320
tggatcctgg ctggaggggc ccaccatacc gtttacacac aggcattaac gactgaattc 1380
ttggaggatt ttgcggacat agctggtatt gaacttctcg tcatcgatga caaaacctcg 1440
ataagagagt tcaaggataa aattaacgcc aatgaagcat attaccacat gtttcaacat 1500
ggcatgcacc atcaccatca ccat 1524
<210> 3
<211> 506
<212> PRT
<213> Massilia glaciei
<400> 3
Met Lys Thr Tyr Gly Glu Lys Glu Val Trp Leu Val Thr Gly Ser Gln
1 5 10 15
His Leu Tyr Gly Pro Gly Val Leu Gln Gln Val Ala Ala Asn Ser Ala
20 25 30
His Ile Ala Glu Gln Leu Thr Gly Ser Pro Asn Ile Pro Ile Arg Ile
35 40 45
Val Ala Lys Asp Val Val Lys Ser Pro Gly Glu Ile Leu Ser Val Cys
50 55 60
Gln Ala Ala Asn Ser Asp Ala Asn Cys Val Gly Leu Ile Leu Trp Met
65 70 75 80
His Thr Phe Ser Pro Ala Lys Met Trp Ile Ala Gly Leu Ser Val Leu
85 90 95
Ser Lys Pro Tyr Met His Leu His Thr Gln Phe Asn Ala Glu Leu Pro
100 105 110
Phe Ala Asp Ile Asp Met His Phe Met Asn Leu Asn Gln Ser Ala His
115 120 125
Gly Asp Arg Glu Phe Gly His Val Ser Thr Arg Leu Lys Gln Glu Arg
130 135 140
Lys Val Val Val Gly His Trp Ala Ala Pro Ala Val Gln Leu Glu Ile
145 150 155 160
Asp Ser Trp Cys Arg Val Ala Met Gly Trp His Glu Ser Arg Asn Leu
165 170 175
Arg Val Ala Arg Phe Gly Asp Asn Met Arg Gln Val Ala Val Thr Asp
180 185 190
Gly Asp Lys Val Ala Ala Gln Ile Gln Phe Gly Tyr Glu Val His Ala
195 200 205
Tyr Gly Leu Gly Asp Leu Gln Lys Val Val Asp Ala Val Thr Asp Glu
210 215 220
Gln Val Ala Arg Gln Ile Ala Val Tyr Gln Glu Ala Tyr Glu Ile Ala
225 230 235 240
Pro Ser Met Leu Gly Asp Ala His Gln Met Glu Met Ile Glu Asn Glu
245 250 255
Ala Arg Leu Glu Leu Gly Met Leu Ala Phe Leu Gln Asp Gly Gly Phe
260 265 270
Gly Ala Phe Thr Asn Cys Phe Glu Asn Leu Thr Gly Leu Thr Asn Leu
275 280 285
Pro Gly Leu Ala Thr Gln Arg Leu Met Ala Gln Gly Tyr Gly Tyr Gly
290 295 300
Gly Glu Gly Asp Trp Lys Thr Ala Ala Met Val Arg Ile Ala Lys Val
305 310 315 320
Met Ser Lys Gly Arg Pro Gly Gly Ser Ser Phe Met Glu Asp Tyr Thr
325 330 335
Tyr His Phe Gly Val Val Asp Gln Val Leu Gly Ala His Met Leu Glu
340 345 350
Val Cys Pro Ser Ile Ala Ala Ala Arg Pro Lys Leu Glu Val His Leu
355 360 365
His Thr Ile Gly Cys Arg Asn Asp Ile Ala Arg Leu Leu Phe Thr Gly
370 375 380
Lys Ala Gly Pro Ala Leu Cys Ile Ser Leu Ile Asp Leu Gly Asn Arg
385 390 395 400
Phe Arg Met Ile Ile Ser Glu Val Asp Thr Val Thr Pro Glu His Glu
405 410 415
Leu Pro Lys Leu Pro Val Ala Lys Ala Leu Trp Gln Pro Arg Pro Asn
420 425 430
Leu Gln Val Ala Ala Ala Ala Trp Ile His Ala Gly Gly Ala His His
435 440 445
Ser Thr Tyr Thr Gln Gly Ile Thr Ala Glu Glu Ala Gln Asp Phe Ala
450 455 460
Asp Ile Ala Gly Ile Glu Ala Val Val Ile Gly Ala Gly Thr Ser Val
465 470 475 480
Arg Gly Met Lys Thr Asp Leu Arg His Asn Ala Ala Tyr Tyr His Leu
485 490 495
Lys Asp Gly Val His His His His His His
500 505
<210> 4
<211> 1518
<212> DNA
<213> Massilia glaciei
<400> 4
atgaaaactt atggtgaaaa ggaggtttgg ttagtcaccg gctctcaaca tttgtacgga 60
cctggggtac ttcagcaagt ggctgccaat tccgcacaca ttgcggaaca gctcacaggt 120
tcacccaaca tcccaatacg tattgttgct aaagatgtcg taaagtcgcc gggcgagatc 180
ctaagtgtgt gtcaagccgc aaatagcgac gcgaactgcg ttggactgat attatggatg 240
catacgtttt ctcctgctaa aatgtggatt gccgggttgt ccgtcctttc aaagccctat 300
atgcacctcc atactcagtt caatgcagaa ctaccatttg cggatatcga catgcacttc 360
atgaacctga atcaatcggc tcatggtgat cgcgagtttg gccacgtaag tacccgatta 420
aaacaggaac ggaaggtggt tgtcggacat tgggccgcac cggcggtaca attggagata 480
gacagctggt gtagagtggc tatggggtgg cacgaatcta ggaaccttcg tgttgcccgc 540
ttcggtgata atatgcgaca ggtcgcagta acagacggcg ataaagtggc ggctcaaatt 600
cagtttggat acgaggttca tgcctatggg ctcggtgacc tacaaaaggt cgtagatgca 660
gtgacggacg aacaggttgc gcggcaaatc gctgtctacc aggaggccta tgaaatagca 720
ccttccatgc tgggcgatgc gcaccaaatg gagatgattg aaaacgaggc tagattagaa 780
ttgggaatgc ttgccttcct ccaggacggg ggttttggcg cattcactaa ttgctttgag 840
aacctaaccg gactgacaaa tttacccggg ttggcgacgc aaaggcttat ggctcagggt 900
tacggctatg gaggggaagg tgattggaaa actgccgcaa tggtacgtat cgcgaaggtg 960
atgtcaaaag gccgcccagg agggtcgagt ttcatggagg actacaccta tcattttggt 1020
gttgtcgatc aagtactcgg cgctcacatg ctagaagtgt gtccgagcat agccgcagcg 1080
cgacctaagc tggaggttca tttacacaca attggatgcc ggaacgacat cgctagattg 1140
cttttcacgg ggaaagccgg tcccgcactc tgtatatctc taattgatct gggcaatagg 1200
tttcgtatga tcatatccga agtcgacact gtaaccccag agcatgaatt accgaagttg 1260
cctgtggcga aagctctttg gcagccccgc ccaaacctcc aagttgccgc agcggcttgg 1320
attcacgccg gaggggcaca tcactcaaca tacacgcagg gtatcactgc ggaggaagct 1380
caagatttcg ccgacatagc aggcattgag gcggtcgtaa tcggagctgg gacctcggtg 1440
cgaggtatga agacagatct acggcataat gccgcatatt accacctgaa agacggcgtt 1500
catcaccatc accatcac 1518
<210> 5
<211> 507
<212> PRT
<213> Chitinophagaceae bacterium
<400> 5
Met Lys His Ile Ile Thr Ser Ala Gly Ala Ala Leu Glu Val Trp Phe
1 5 10 15
Val Thr Gly Ser Gln His Leu Tyr Gly Glu Glu Thr Leu Lys Gln Val
20 25 30
Ala Glu His Ser Arg Gln Ile Ala Ala Ser Leu His Glu Ala Ala Ala
35 40 45
Ile Pro Val Asn Val Val Phe Lys Pro Thr Val Lys Thr Pro Asp Glu
50 55 60
Ile Tyr Gln Val Cys Val Asp Ala Asn Thr Thr Lys Asn Cys Ile Gly
65 70 75 80
Val Ile Thr Trp Met His Thr Phe Ser Pro Ala Lys Met Trp Ile Gly
85 90 95
Gly Leu Lys Val Leu Gln Lys Pro Leu Cys His Leu His Thr Gln Phe
100 105 110
Asn Arg Asp Ile Pro Trp Gly Asp Ile Asp Met Asp Phe Met Asn Leu
115 120 125
Asn Gln Ser Ala His Gly Asp Arg Glu Tyr Gly Phe Ile Met Ser Arg
130 135 140
Met Arg Leu Arg Arg Lys Val Val Val Gly His Trp Gln Asp Glu Gln
145 150 155 160
Val Val Ala Gly Ile Ala Ser Trp Val Arg Ala Ala Ala Gly Trp Asn
165 170 175
Asp Trp Gln Gly Ala Arg Phe Val Arg Phe Gly Asp Asn Met Arg Gln
180 185 190
Val Ala Val Thr Glu Gly Asp Lys Val Glu Ala Glu Leu Gln Phe Gly
195 200 205
Tyr Ser Val Asn Thr His Gly Ile Gly Asp Leu Val Lys Val Ile Asn
210 215 220
Glu Val Thr Asp Ala Asp Val Asp Lys Leu Cys Ala Asn Tyr Asp Glu
225 230 235 240
Gln Tyr Lys Leu Val Ala Ser Leu Lys Lys Gly Gly Asp Gln His Glu
245 250 255
Ser Leu Lys Asp Ala Ala Arg Ile Glu Leu Gly Leu Arg Tyr Phe Leu
260 265 270
Glu Gln Gly Asn Phe Lys Gly Phe Thr Asp Thr Phe Glu Asp Leu His
275 280 285
Gly Met Lys Gln Leu Pro Gly Ile Ala Thr Gln Arg Leu Met Ala Asp
290 295 300
Gly Tyr Gly Phe Gly Gly Glu Gly Asp Trp Lys Thr Ser Ala Leu Val
305 310 315 320
Arg Ala Met Lys Val Met Gly Ser Gly Leu Gln Gly Gly Asn Ser Phe
325 330 335
Met Glu Asp Tyr Thr Tyr His Phe Glu Pro Gly Asn Asn Leu Val Leu
340 345 350
Gly Ser His Met Leu Glu Ile Cys Pro Ser Ile Ala Asp Gly Lys Pro
355 360 365
Ser Cys Glu Ile His Pro Leu Gly Ile Gly Gly Lys Ala Asp Pro Val
370 375 380
Arg Leu Val Phe Asn Val Ala Ala Gly Pro Ala Ile Asn Ala Ser Val
385 390 395 400
Ile Asp Met Gly Asn Arg Phe Arg Leu Leu Val Asn Glu Val Glu Ala
405 410 415
Val Ala Pro Leu His Asp Leu Pro Arg Leu Pro Val Ala Arg Val Leu
420 425 430
Trp Lys Pro Leu Pro Asp Met Gln Thr Ala Leu Ala Ala Trp Ile Leu
435 440 445
Ala Gly Gly Ala His His Thr Gly Tyr Ser Gln Asn Leu Thr Ala Glu
450 455 460
His Leu Glu Asp Phe Ala Asp Ile Ala Lys Ile Glu Phe Val Leu Ile
465 470 475 480
Gly Lys Asn Thr Asn Leu Tyr Gln Leu Lys Asn Glu Leu Arg Trp Ser
485 490 495
Glu Ile Ala Tyr Lys His His His His His His
500 505
<210> 6
<211> 1521
<212> DNA
<213> Chitinophagaceae bacterium
<400> 6
atgaaacata ttatcacttc tgctggtgcc gcattagaag tttggtttgt caccggctcc 60
caacacttgt atggagagga aacacttaag caggtagcgg agcattcacg tcaaatagct 120
gcctcgctcc acgaagcagc ggctattcct gtgaatgttg tcttcaaacc cacggtaaag 180
actccagatg agatctacca ggtgtgtgtt gacgccaaca ccacaaaaaa ttgcataggg 240
gtcattacgt ggatgcatac ttttagtccg gcaaagatgt ggatcggtgg cctaaaagta 300
ctgcaaaagc ctttatgtca cttgcatacc cagttcaacc gcgatatacc ctggggagac 360
attgatatgg actttatgaa tcttaaccaa agcgcgcacg gggatcgaga atatggtttc 420
atcatgtctc ggatgagact caggcgtaaa gtggttgtcg gccattggca ggacgagcaa 480
gtagtggctg gaatagcctc ctgggttcgc gcagcggctg ggtggaatga ttggcagggt 540
gcccgatttg tccggttcgg cgacaacatg agacaagtag cagtgacaga aggagataag 600
gttgaggcgg aactacagtt tgggtactca gtcaatacgc acggtattgg cgacctggta 660
aaagtgatca acgaggttac tgatgctgac gtcgataagt tatgcgccaa ttatgacgaa 720
caatacaaat tggtagcatc gcttaagaaa ggaggggatc agcatgagag tctcaaggac 780
gcggctagga tagaactagg tctgcgttat ttcttagagc aaggcaactt taaaggattc 840
accgatacat ttgaagactt gcacgggatg aagcagcttc caggtattgc cacgcaacgc 900
ctcatggcag atggctacgg attcgggggt gagggcgact ggaaaactag cgcgctagtg 960
cgagctatga aggttatggg atctgggctg cagggtggca attcctttat ggaagattat 1020
acctaccatt tcgagccggg aaacaattta gtcttggggt cacacatgct tgaaatctgt 1080
ccttcgatag ccgacggtaa acccagttgc gagattcatc cactcggcat cggagggaag 1140
gcagatccgg tacggctagt gtttaacgtt gcggctggtc ctgccataaa tgcaagcgtc 1200
attgacatgg gcaacagatt caggctgtta gtaaatgaag tggaggcggt tgctcccttg 1260
cacgatcttc cacgtctccc ggtcgcccgc gtactatgga aacctctgcc cgacatgcaa 1320
acagcattag cggcttggat cttggccgga ggggcacatc acacgggtta ttctcagaac 1380
cttactgcgg aacatctcga ggattttgct gacatagcca agattgaatt cgtgctaatc 1440
ggcaaaaata ccaacctgta ccaattaaag aatgagttgc gatggtccga aatagcatat 1500
aaacaccatc accatcacca t 1521
<210> 7
<211> 507
<212> PRT
<213> 人工序列(Unknown)
<400> 7
Met Lys His Ile Ile Thr Ser Ala Gly Ala Ala Leu Glu Val Trp Phe
1 5 10 15
Val Thr Gly Ser Gln His Leu Tyr Gly Glu Glu Thr Leu Lys Gln Val
20 25 30
Ala Glu His Ser Arg Gln Ile Ala Ala Ser Leu His Glu Ala Ala Ala
35 40 45
Ile Pro Val Asn Val Val Phe Lys Pro Thr Val Lys Thr Pro Asp Glu
50 55 60
Ile Tyr Gln Val Cys Val Asp Ala Asn Thr Thr Lys Asn Cys Ile Gly
65 70 75 80
Val Ile Thr Trp Met His Thr Phe Ser Pro Ala Lys Met Trp Ile Gly
85 90 95
Lys Leu Lys Val Leu Gln Lys Pro Leu Cys His Leu His Thr Gln Phe
100 105 110
Asn Arg Asp Ile Pro Trp Gly Asp Ile Asp Met Asp Phe Met Asn Leu
115 120 125
Asn Gln Ser Ala His Gly Asp Arg Glu Tyr Gly Phe Ile Met Ser Arg
130 135 140
Met Arg Leu Arg Arg Lys Val Val Val Gly His Trp Gln Asp Glu Gln
145 150 155 160
Val Val Ala Gly Ile Ala Ser Trp Val Arg Ala Ala Ala Gly Trp Asn
165 170 175
Asp Trp Gln Gly Ala Arg Phe Val Arg Phe Gly Asp Ser Met Arg Gln
180 185 190
Val Ala Val Thr Glu Gly Asp Lys Val Glu Ala Glu Leu Gln Phe Gly
195 200 205
Tyr Ser Val Asn Thr His Gly Ile Gly Asp Leu Val Lys Val Ile Asn
210 215 220
Glu Val Thr Asp Ala Asp Val Asp Lys Leu Cys Ala Asn Tyr Asp Glu
225 230 235 240
Gln Tyr Lys Leu Val Ala Ser Leu Lys Lys Gly Gly Asp Gln His Glu
245 250 255
Ser Leu Lys Asp Ala Ala Arg Ile Glu Leu Gly Leu Arg Tyr Phe Leu
260 265 270
Glu Gln Gly Asn Phe Lys Gly Phe Thr Asp Thr Phe Glu Asp Leu His
275 280 285
Gly Met Lys Gln Leu Pro Gly Ile Ala Thr Gln Arg Glu Met Ala Asp
290 295 300
Gly Tyr Gly Phe Gly Gly Glu Gly Asp Trp Lys Thr Ser Ala Leu Val
305 310 315 320
Arg Ala Met Lys Val Met Gly Ser Gly Leu Gln Gly Gly Asn Ser Phe
325 330 335
Met Glu Asp Tyr Thr Tyr His Phe Glu Pro Gly Asn Asn Leu Val Leu
340 345 350
Gly Ser His Met Leu Glu Ile Cys Pro Ser Ile Ala Asp Gly Lys Pro
355 360 365
Ser Cys Glu Ile His Pro Leu Gly Ile Gly Gly Lys Ala Asp Pro Val
370 375 380
Arg Leu Val Phe Asn Val Ala Ala Gly Pro Ala Ile Asn Ala Ser Val
385 390 395 400
Ile Asp Met Gly Asn Arg Phe Arg Pro Leu Val Asn Glu Val Glu Ala
405 410 415
Val Ala Pro Leu His Asp Leu Pro Arg Leu Pro Val Ala Arg Val Leu
420 425 430
Trp Lys Pro Leu Pro Asp Met Gln Thr Ala Leu Ala Ala Trp Ile Leu
435 440 445
Ala Gly Gly Ala His His Thr Gly Tyr Ser Gln Asn Leu Ala Ala Glu
450 455 460
His Leu Glu Asp Phe Ala Asp Ile Ala Lys Ile Glu Phe Val Leu Ile
465 470 475 480
Gly Lys Asn Thr Asn Leu Tyr Gln Leu Lys Asn Glu Leu Arg Trp Ser
485 490 495
Glu Ile Ala Tyr Lys His His His His His His
500 505
<210> 8
<211> 1521
<212> DNA
<213> 人工序列(Unknown)
<400> 8
atgaaacata ttattaccag cgcgggcgcg gcgctggaag tgtggtttgt gaccggcagc 60
cagcatctgt atggcgaaga aaccctgaaa caggtggcgg aacatagccg tcagattgcg 120
gcgagcctgc atgaagcggc ggcgattccg gtgaacgtgg tgtttaaacc gaccgtgaaa 180
accccggatg aaatttatca ggtgtgcgtg gatgcgaaca ccaccaaaaa ctgcattggc 240
gtgattacct ggatgcatac ctttagcccg gcgaaaatgt ggattggcaa actgaaagtg 300
ctgcagaaac cgctgtgcca tctgcatacc cagtttaacc gtgatattcc gtggggcgat 360
attgatatgg attttatgaa cctgaaccag agcgcgcatg gcgatcgtga atatggcttt 420
attatgagcc gtatgcgtct gcgtcgtaaa gtggtggtgg gccattggca ggatgaacag 480
gtggtggcgg gcattgcgag ctgggtgcgt gcggcggcgg gctggaacga ttggcagggc 540
gcgcgttttg tgcgttttgg cgatagcatg cgtcaggtgg cggtgaccga aggcgataaa 600
gtggaagcgg aactgcagtt tggctatagc gtgaacaccc atggcattgg cgatctggtg 660
aaagtgatta acgaagtgac cgatgcggat gtggataaac tgtgcgcgaa ctatgatgaa 720
cagtataaac tggtggcgag cctgaaaaaa ggcggcgatc agcatgaaag cctgaaagat 780
gcggcgcgta ttgaactggg cctgcgttat tttctggaac agggcaactt taaaggcttt 840
accgatacct ttgaagatct gcatggcatg aaacagctgc cgggcattgc gacccagcgt 900
gaaatggcgg atggctatgg ctttggcggc gaaggcgatt ggaaaaccag cgcgctggtg 960
cgtgcgatga aagtgatggg cagcggcctg cagggcggca acagctttat ggaagattat 1020
acctatcatt ttgaaccggg caacaacctg gtgctgggca gccatatgct ggaaatttgc 1080
ccgagcattg cggatggcaa accgagctgc gaaattcatc cgctgggcat tggcggcaaa 1140
gcggatccgg tgcgtctggt gtttaacgtg gcggcgggcc cggcgattaa cgcgagcgtg 1200
attgatatgg gcaaccgttt tcgtccgctg gtgaacgaag tggaagcggt ggcgccgctg 1260
catgatctgc cgcgtctgcc ggtggcgcgt gtgctgtgga aaccgctgcc ggatatgcag 1320
accgcgctgg cggcgtggat tctggcgggc ggcgcgcatc ataccggcta tagccagaac 1380
ctggcggcgg aacatctgga agattttgcg gatattgcga aaattgaatt tgtgctgatt 1440
ggcaaaaaca ccaacctgta tcagctgaaa aacgaactgc gttggagcga aattgcgtat 1500
aaacatcatc atcatcatca t 1521

Claims (5)

1.一种L-阿拉伯糖差向异构酶突变体,由序列如SEQ ID NO.5所示氨基酸经定点突变而来,所述突变的位点为下列之一:
(1)第97位甘氨酸G突变为赖氨酸K;
(2)第97位甘氨酸G突变为赖氨酸K+第189位天冬氨酸N突变为丝氨酸S;
(3)第97位甘氨酸G突变为赖氨酸K+第189位天冬氨酸N突变为丝氨酸S+第301位亮氨酸L突变为谷氨酸E;
(4)第97位甘氨酸G突变为赖氨酸K+第189位天冬氨酸N突变为丝氨酸S+第301位亮氨酸L突变为谷氨酸E+第409位亮氨酸L突变为脯氨酸P;
(5)第97位甘氨酸G突变为赖氨酸K+第189位天冬氨酸N突变为丝氨酸S+第301位亮氨酸L突变为谷氨酸E+第409位亮氨酸L突变为脯氨酸P+第462位苏氨酸T突变为丙氨酸A。
2.如权利要求1所述的L-阿拉伯糖差向异构酶突变体,其特征在于所述L-阿拉伯糖差向异构酶突变体序列如SEQ ID NO. 7所示。
3.权利要求1或2所述L-阿拉伯糖差向异构酶突变体在催化D-半乳糖异构化制备D-塔格糖中的应用。
4.如权利要求3所述的应用,其特征在于所述应用为:以含L-阿拉伯糖差向异构酶编码基因的重组基因工程菌经发酵培养获得的湿菌体或湿菌体经超声破碎后获得的上清液作为催化剂,以D-半乳糖为底物,在Mn2+存在下,在6.0~7.0 的Na2HPO4-NaH2PO4缓冲液中,70~85℃温度下反应,反应结束后,反应液分离纯化,获得D-塔格糖。
5.如权利要求4所述的应用,其特征在于所述L-阿拉伯糖差向异构酶突变体编码基因序列如SEQ ID NO. 8所示。
CN201911383972.2A 2019-12-28 2019-12-28 L-阿拉伯糖差向异构酶突变体及其应用 Active CN110904087B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911383972.2A CN110904087B (zh) 2019-12-28 2019-12-28 L-阿拉伯糖差向异构酶突变体及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911383972.2A CN110904087B (zh) 2019-12-28 2019-12-28 L-阿拉伯糖差向异构酶突变体及其应用

Publications (2)

Publication Number Publication Date
CN110904087A CN110904087A (zh) 2020-03-24
CN110904087B true CN110904087B (zh) 2021-05-11

Family

ID=69828202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911383972.2A Active CN110904087B (zh) 2019-12-28 2019-12-28 L-阿拉伯糖差向异构酶突变体及其应用

Country Status (1)

Country Link
CN (1) CN110904087B (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3115453T3 (en) * 2014-03-05 2018-08-06 Cj Cheiljedang Corp L-ARABINOSE ISOMERASE VARIANT FOR PREPARING D-TAGATOSE
US20170114371A1 (en) * 2014-07-10 2017-04-27 Novozymes A/S Process For Producing Ethanol From Starch Using A GH5 Xylanase
US11667680B2 (en) * 2016-03-18 2023-06-06 Lallemand Hungary Liquidity Management Llc Regulation of the RAS/cAMP/PKA signaling pathway in yeasts for obtaining a fermentation product during fermentation
WO2018117773A2 (ko) * 2016-12-23 2018-06-28 경북대학교 산학협력단 변형된 당 대사 경로를 갖는 재조합 균주 및 이를 이용한 당이성화 효소의 스크리닝 방법
WO2019058260A1 (en) * 2017-09-19 2019-03-28 Lallemand Hungary Liquidity Management Llc TOLERANCE TO ACETATE TOXICITY IN RECOMBINANT MICROBIAL HOST CELLS

Also Published As

Publication number Publication date
CN110904087A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
CN110358750B (zh) 新型蔗糖磷酸化酶突变体及其在合成甘油葡糖苷中的应用
CN110862980B (zh) 一种d-阿洛酮糖3-差向异构酶突变体及其应用
CN108048440B (zh) 一种耐高温葡萄糖异构酶突变体及其应用
CN111235126B (zh) 一种s-腺苷甲硫氨酸合成酶突变体及利用其的制备方法
CN113481189B (zh) 一种蔗糖异构酶突变体及其应用
CN113337495B (zh) 一种提高唾液酸产量的方法与应用
CN112831488B (zh) 一种谷氨酸脱羧酶及γ-氨基丁酸高产菌株
CN106566824B (zh) 一种葡萄糖异构酶、基因、载体、工程菌及其应用
CN113151198B (zh) 一种γ-谷酰胺甲胺合成酶的突变体,其编码基因、氨基酸序列及其应用
CN107400667B (zh) 一种含重组耐高温葡萄糖异构酶细胞的固定化方法
CN110904088B (zh) 耐高温d-阿洛酮糖3-差向异构酶、突变体及其应用
CN111394410A (zh) 一种高催化活性神经氨酸合酶及应用
CN111057697B (zh) 耐高温TIM barrel蛋白突变体及其应用
CN110904087B (zh) L-阿拉伯糖差向异构酶突变体及其应用
CN114807099B (zh) 普鲁兰酶突变体、工程菌及其应用
CN113151240B (zh) 一种葡萄糖异构酶、突变体及其编码基因与应用
CN106119235B (zh) 一种来源于伯克霍尔德氏菌的dpe及其应用
CN108034649B (zh) 一种葡萄糖异构酶突变体及其应用
CN114836406A (zh) 一种催化活力提高的琼胶酶突变体及其应用
CN111057698B (zh) L-阿拉伯糖异构酶、突变体及其应用
CN110951717B (zh) 一种l-阿拉伯糖异构酶异构体及其应用
CN110452899B (zh) 一种葡萄糖异构酶、突变体及其在制备d-果糖中的应用
CN110804602A (zh) 一种L-天冬氨酸β-脱羧酶突变体及其应用
CN115261366B (zh) 一种耐高温纤维二糖差向异构酶突变体、工程菌及其应用
CN114107270B (zh) 一种L-天冬氨酸β-脱羧酶突变体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant